

# Kidney and Bladder Cancer: Targeted, Immuno & Other Strategies

Pedro C. Barata, MD, MSc, FACP Director of GU Medical Oncology Research Program Co-Leader GU Disease Team University Hospitals Seidman Cancer Center Associate Professor of Medicine Case Western Reserve University







## Outline


- Renal Cell Carcinoma
- Urothelial Carcinoma







## Treatment Landscape of Metastatic RCC



# Refractory Setting








## HIF-2α Inhibition in Renal Cell Carcinoma

- The HIF pathway is central to the pathophysiology of clear cell renal cell carcinoma (ccRCC) and von Hippel-Lindau (VHL) disease
- Belzutifan, a model of bench to bedside development, is a first-in-class oral HIF-2α inhibitor that blocks heterodimerization with HIF-1β and downstream oncogenic pathways<sup>1,2</sup>
  - Approved in the US for certain VHL diseaseassociated RCC, pNET and CNS-HB
  - Demonstrated clinical activity in pretreated advanced ccRCC<sup>2-5</sup>



CNS-HB, central nervous system hemangioblastoma; pNET, pancreatic neuroendocrine tumor; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor. 1. Jonasch et al. *New Eng J Med* 2021;385:2036-2046; 2. Choueiri et al. *Nat Med* 2021;27:802-805; 3. Agarwal et al. ESMO 2023; Presentation 1881O; 4. Choueiri et al. *Lancet Oncol* 2023;24:553-562; 5. Choueiri et al. ESMO 2023; Presentation 1881O; 4. Choueiri et al. *Lancet Oncol* 2023;24:553-562; 5. Choueiri et al. ESMO 2023; Presentation 1881O; 4. Choueiri et al. *Lancet Oncol* 2023;24:553-562; 5. Choueiri et al. ESMO 2023; Presentation LBA87.

Albiges et al, ESMO 2023








## Belzutifan in Refractory RCC (Choueiri T et al, Nature 2021)

Study Population			
Advanced RCC			
≥1 prior line of therapy (median, 3)			
Any risk group (intermediate, 73%)			


	Belzutifan (Phase 1/2 Trial)
Ν	55
Median (range) treatment line	3 (1-9)
Median follow-up	28 months
ORR	25% (14 confirmed PRs)
Disease control rate	80%
Median PFS (overall)	14.5 months
Median DOR	NR
Most common AEs	Anemia (76%) and fatigue (71%)
Most common grade 3 AEs	Anemia (27%) and hypoxia (16%)







## LITESPARK-005 Study (NCT04195750)



### **Stratification Factors**

• IMDC prognostic score<sup>a</sup>: 0 vs 1-2 vs 3-6

• Prior VEGF/VEGFR-targeted therapies: 1 vs 2-3

### **Dual Primary Endpoints:**

- PFS per RECIST 1.1 by BICR
- OS

### Key Secondary Endpoint:

• ORR per RECIST 1.1 by BICR

### **Other Secondary Endpoints Include:**

- DOR per RECIST 1.1 by BICR
- Safety
- Time to deterioration in FKSI-DRS and EORTC QLQ-C30 GHS/QoL

<sup>a</sup> Based on the number of present risk factors according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).


BICR, blinded independent central review; DOR, duration of response; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire; FKSI-DRS, Functional Assessment of Cancer Therapy Kidney Symptom Index – Disease-Related Symptoms; GHS, global health status; mAb, monoclonal antibody; QoL, quality of life.

### Albiges et al, ESMO 2023









## **Baseline Characteristics**


	Belzutifan (N = 374)	Everolimus (N = 372)
Age, median (range), yrs	62 (22–90)	63 (33–87)
Male	79.4%	76.3%
KPS score <sup>a</sup> 90/100 70/80	63.6% 36.1%	64.5% 35.2%
IMDC risk categories Favorable Intermediate Poor	21.1% 66.6% 12.3%	22.3% 65.6% 12.1%
Sarcomatoid features Yes No/Unknown/Missing	11.2% 88.8%	8.3% 91.7%
Prior nephrectomy	69.8%	69.6%
# Prior VEGF/VEGFR-TKIs 1 2-3	50.0% 50.0%	51.1% 48.9%
# Prior lines of therapy <sup>b</sup> 1 2 3	12.3% 42.0% 45.2%	14.0% 44.6% 40.3%

<sup>a</sup> 0.3% pts in each arm had a missing KPS score. <sup>b</sup> 0.5% of pts in the belzutifan arm and 1.1% in the everolimus arm had 4 prior lines of therapy (protocol violation). Data cutoff date for IA2: June 13, 2023.











## Primary Endpoint: PFS per RECIST 1.1 by BICR

Kaplan-Meier Estimate of PFS at IA2



# Key Secondary Endpoint: ORR by BICR per RECIST 1.1



\* Insufficient data for response assessment per REUST 1.1. \* No post-baseline assessment available.

\* denotes statistical significance. CR, complete response; PR, partial response. Data cutoff date for IA1: November 1, 2022. Data cutoff date for IA2: June 13, 2023.



**University Hospitals** Seidman Cancer Center






### Salvage PD-L1 Inhibitor is not superior to TKI alone

## **CONTACT-03**

- Histologically confirmed advanced, metastatic ccRCC or nccRCC
- Radiographic progression during or following ICI treatment



No crossover allowed


## **Negative Trial**

### **Treatment until progression**

- Primary endpoint: PFS, OS
- Secondary endpoint: PFS, ORR, DoR, Safety and Tolerability

### **TINIVO-2**

- Histologically/cytologically confirmed recurrent/ metastatic RCC
- ECOG PS 0 or 1
- Progressed following immediate prior immunotherapy treatment in first or second line
- Stratified by IMDC and prior TKI



### Completed enrollment Spring 2023


### **Treatment until progression**

- Primary endpoint: PFS
- Secondary endpoint: OS, ORR, DoR, Safety and Tolerability


# Adjuvant








## Adjuvant IO Trials



Tacconi EMC, et al. Onco Targets Ther. 2020;13:12301-12316.



# Urothelial Carcinoma







## EV-103 Cohort K: Efficacy

	<b>EV + Pembro</b> <sup>1</sup> N=76	EV Mono <sup>1</sup> N=73
Confirmed ORR (95% Cl)	49 ( <b>64.5%</b> ) (52.7-75.1)	33 (45.2%) (33.5-57.3)
Best overall response		
CR	8 (10.5%)	4 (5.5%)
PR	41 (53.9%)	29 (39.7%)
SD	17 (22.4%)	25 (34.2%)
PD	6 (7.9%)	7 (9.6%)
NE	3 (3.9%)	5 (6.8%)
No assessment	1 (1.3%)	3 (4.1%)
Median time to objective response, mo (range)	2.07 (1.1-6.6)	2.07 (1.9-15.4)
Median number of treatment cycles (range)	12.0 (1-34)	8.0 (1-33)


• EV + Pembro arm: 7/13 (53.8%) confirmed ORR observed in patients with liver metastases<sup>1</sup>

No formal statistical comparisons were conducted between the two treatment arms

1. Friedlander TW, et al. ASCO 2023. Abstract 4568. 2. Rosenberg JE, et al. ESMO 2022. Abstract LBA73.







**EV + Pembro: Maximum Percent Reduction** 


From Baseline of Target Lesion by BICR<sup>2</sup>

	<b>EV + Pembro</b> <sup>1</sup> N=76	<b>EV Mono</b> <sup>1</sup> N=73
<b>mDOR</b> , mo (95% CI)	<b>NR</b> (10.25-NR)	13.2 (6.14-NR)
<b>mPFS</b> , mo (95% CI)	<b>NR</b> (8.31-NR)	8.2 (6.05-15.28)
<b>mOS</b> , mo (95% Cl)	<b>NR</b> (21.39-NR)	21.7 (15.47-NR)
Median follow-up, mo	17.6	18.2

Pedro C. Barata, MD MSc

100 -

80




PD-L1 Score High (CPS ≥10) Low (CPS <10)</li>

Not evaluable Best Overall Response

Confirmed CR/PE

# EV-302/KEYNOTE-A39 (NCT04223856)



Stratification factors: cisplatin eligibility (eligible/ineligible), PD-L1 expression (high/low), liver metastases (present/absent)

Cisplatin eligibility and assignment/dosing of cisplatin vs carboplatin were protocol-defined; patients received 3-week cycles of EV (1.25 mg/kg; IV) on Days 1 and 8 and P (200 mg; IV) on Day 1

Statistical plan for analysis: the first planned analysis was performed after approximately 526 PFS (final) and 356 OS events (interim); if OS was positive at interim, the OS interim analysis was considered final

 Powles T et al, ESMO 2023
 BICR, blinded independent central review; ECOG PS, Eastern Cooperative Oncology Group performance status; GFR, glomerular filtration rate; ORR, overall response rate; PFS, progression-free survival; R, randomization; RECIST, Response Evaluation Criteria in Solid Tumors

 aMeasured by the Cockcroft-Gault formula, Modification of Diet in Renal Disease, or 24-hour urine
 bPatients with ECOG PS of 2 were required to also meet the additional criteria: hemoglobin ≥10 g/dL, GFR ≥50mL/min, may not have NYHA class III heart failure

 cMaintenance therapy could be used following completion and/or discontinuation of platinum-containing therapy










# **Progression-Free Survival per BICR**


Risk of progression or death was reduced by 55% in patients who received EV+P






ษ





## **Overall Survival**


Risk of death was reduced by 53% in patients who received EV+P



University Hospitals Seidman Cancer Center

Ы

SCHOOL OF MEDICINE CASEWESTERN RESERVE



# **Subgroup Analysis of OS**

OS benefit in select pre-specified subgroups was consistent with results in overall population

		Events/N		
Subgroup	EV+P	Chemotherapy	Hazard Ratio	(95% CI)
Overall	133/442	226/444	<b>⊢</b> ∎	0.47 (0.38-0.58)
Age				
<65 years	39/144	58/135	<b>⊢</b>	0.46 (0.30-0.71)
≥65 years	94/298	168/309	<b>⊢</b> ∎−−1	0.48 (0.38-0.63)
Sex				
Female	32/98	54/108	<b>⊢−−−</b> ∎−−−−4	0.51 (0.32-0.80)
Male	101/344	172/336	<b>— — — — —</b>	0.47 (0.36-0.60)
ECOG PS				
0	44/223	94/215	<b>⊢</b>	0.36 (0.25-0.53)
1-2	89/219	131/227	<b>⊢ −</b> − 1	0.54 (0.41-0.72)
Primary disease site of origin				
Upper tract	38/135	45/104	<b>⊢</b> (	0.53 (0.34-0.83)
Lower tract	94/305	180/339		0.46 (0.36-0.59)
Liver metastases				• ********
Present	43/100	67/99	<b>⊢</b>	0.47 (0.32-0.71)
Absent	90/342	159/345	<b>⊢</b> ∎−−1	0.47 (0.36-0.61)
PD-L1 expression				
Low (CPS <10)	53/184	99/185	<b>⊢</b>	0.44 (0.31-0.61)
High (CPS ≥10)	79/254	125/254	<b>⊢</b>	0.49 (0.37-0.66)
Cisplatin eligibility				
Eligible	69/244	106/234		0.53 (0.39-0.72)
Ineligible	64/198	120/210	<b>⊢_</b> ∎{	0.43 (0.31-0.59)
a na ana ao amin' 🚍 an an ann			<u> </u>	<u> </u>
wles T et al, ESMO 2023		0.1	5 mm 51/1 D	5
a cutoff: 08 Aug 2023			Favors EV+P	Favors chemotherapy








# **Confirmed Overall Response per BICR**

Significant improvement in objective response rate was observed with EV+P



	EV+P (N=437)	Chemotherapy (N=441)
Confirmed ORR, n (%) (95% Cl)	296 (67.7) (63.1-72.1)	196 (44.4) (39.7-49.2)
2-sided P value	<0.00001	
Best overall response <sup>a</sup> , n (%)		
Complete response	127 (29.1)	55 (12.5)
Partial response	169 (38.7)	141 (32.0)
Stable disease	82 (18.8)	149 (33.8)
Progressive disease	38 (8.7)	60 (13.6)
Not evaluable/No assessment <sup>b</sup>	21 (4.8)	36 (8.2)

CR, complete response; DOR, duration of response; PR, partial response

<sup>a</sup>Best overall response according to RECIST v1.1 per BICR. CR or PR was confirmed with repeat scans ≥28 days after initial response <sup>b</sup>Patients had either post-baseline assessment and the best overall response was determined to be not evaluable per RECIST v1.1 or no response assessment post-baseline

Data cutoff: 08 Aug 2023

Powles T et al, ESMO 2023







# **Summary & Conclusions**


- EV-302/KEYNOTE-A39 is the first time that platinum-based chemotherapy has been surpassed in OS in patients with previously untreated la/mUC
- EV+P showed statistically significant and clinically meaningful improvement in efficacy over chemotherapy
  - PFS HR: 0.45; OS HR: 0.47
  - mPFS and mOS were nearly doubled in the EV+P arm compared with chemotherapy
  - Benefit in prespecified subgroups and stratification factors was consistent with the overall population
- The safety profile of EV+P was generally manageable, with no new safety signals observed
- These results support EV+P as a potential new standard of care for 1L la/mUC

Powles T et al, ESMO 2023










### CheckMate 901 Study Design

### • NIVO + gemcitabine-cisplatin vs gemcitabine-cisplatin in cisplatin-eligible patients<sup>a</sup>



Median (range) study follow-up, 33.6 (7.4-62.4) months

**Primary endpoints:** OS, PFS per BICR **Key secondary endpoints:** OS and PFS by PD-L1 ≥ 1%,<sup>d</sup> HRQoL **Key exploratory endpoints:** ORR per BICR, safety


<sup>a</sup>Further CheckMate 901 trial design details are available at https://clinicaltrials.gov/ct2/show/NCT03036098. <sup>b</sup>Patients who discontinued cisplatin could be switched to gemcitabine-carboplatin for the remainder of the platinum doublet cycles (up to 6 in total). <sup>c</sup>A maximum of 24 months from first dose of NIVO administered as part of the NIVO + gemcitabine-cisplatin combination. <sup>d</sup>PD-L1 status was defined by the percentage of positive tumor cell membrane staining in a minimum of 100 tumor cells that could be evaluated with the use of the PD-L1 IHC 28-8 pharmDx immunohistochemical assay (Dako, Santa Clara, CA, USA).

BICR, blinded independent central review; D, day; ECOG PS, Eastern Cooperative Oncology Group performance status; HRQoL, health-related quality of life; ORR, objective response rate; PD-L1, programmed death ligand 1; PFS, progression-free survival; Q×W, every × weeks; R, randomization.

Van Der Heijden T et al, ESMO 2023








# OS (primary endpoint)

#### ORIGINAL ARTICLE

#### Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

M.S. van der Heijden, G. Sonpavde, T. Powles, A. Necchi, M. Burotto, M. Schenker, J.P. Sade, A. Bamias, P. Beuzeboc, J. Bedke, J. Oldenburg, G. Chatta, Y. Ürün, D. Ye, Z. He, B.P. Valderrama, J.H. Ku, Y. Tomita, J. Filian, L. Wang, D. Purcea, M.Y. Patel, F. Nasroulah, and M.D. Galsky, for the CheckMate 901 Trial Investigators\*



Median (range) study follow-up was 33.6 (7.4-62.4) months. OS was estimated in all randomized patients and defined as time from randomization to death from any cause. For patients without documented death, OS was censored on the last date the patient was known to be alive. For randomized patients with no follow-up, OS was censored at randomization.




100







## Objective response outcomes (exploratory endpoints)



Any objective response <sup>c</sup>	NIVO+GC (n = 175)	GC (n = 131)
Median TTR (Q1-Q3), months	2.1 (2.0–2.3)	2.1 (2.0–2.2)
Median DoR (95% CI), months	9.5 (7.6–15.1)	7.3 (5.7–8.9)

Complete response <sup>d</sup>	NIVO+GC (n = 66)	GC (n = 36)
Median TTCR (Q1-Q3), months	2.1 (1.9-2.2)	2.1 (1.9-2.2)
Median DoCR (95% CI), months	37.1 (18.1-NE)	13.2 (7.3-18.4)

Van Der Heijden T et al, ESMO 2023


<sup>a</sup>In all randomized patients. <sup>b</sup>The most common reasons for UE response included death before first tumor assessment, withdrawal of consent, treatment stopped due to toxicity, patient never treated, and receipt of subsequent anticancer therapy before first tumor assessment. <sup>c</sup>Based on patients with an objective response per BICR (PR or CR as BOR). <sup>d</sup>Based on patients with a CR per BICR. BOR, best overall response; CR, complete response; DoCR, duration of complete response; DoR, duration of objective response; NE, not estimable; PD, progressive disease; PR, partial response; Q, quartile; SD, stable disease; TTCR, time to complete response; TTR, time to objective response; UE, unevaluable.







Pedro C. Barata, MD MSc



### Time to and duration of responses



# Thank You!!

Pedro.barata@UHhospitals.org